BioCentury | Sep 19, 2016
Clinical News

LB1148: Phase II started

...mL oral LB1148 given 8-10 hours before undergoing elective bowel resection in about 120 patients. Leading BioSciences Inc....
BioCentury | Nov 24, 2014
Clinical News

LB1148 regulatory update

...protease inhibitor to treat multi-organ failure in septic shock and cardiogenic shock following cardiovascular surgery. Leading BioSciences Inc....
BioCentury | Feb 10, 2014
Company News

Leading BioSciences management update

Leading BioSciences Inc. , San Diego, Calif. Business: Inflammation, Diagnostic Hired: Robin Jackman as CEO and a director, formerly president and CEO of Zacharon Pharmaceuticals Inc. , which BioMarin Pharmaceutical Inc. acquired; he succeeds Interim CEO Stephen...
BioCentury | Mar 26, 2012
Clinical News

InflammaGen Shok-Pak: Phase II started

...II trial to compare InflammaGen Shok-Pak vs. standard therapy in about 200 critically-ill ICU patients. Leading BioSciences Inc....
BioCentury | Feb 13, 2012
Company News

Leading BioSciences board of directors update

Leading BioSciences Inc. , Laguna Hills, Calif. Business: Inflammation, Diagnostic Appointed: Stephen Flaim, principal at Flaim Partners Consulting, as chairman WIR Staff Diagnostic Inflammation...
BioCentury | Nov 7, 2011
Clinical News

InflammaGen Shok-Pak: Phase II start

...will begin a placebo-controlled Phase II trial to evaluate InflammaGen Shok-Pak in about 200 patients. Leading BioSciences Inc....
Items per page:
1 - 6 of 6
BioCentury | Sep 19, 2016
Clinical News

LB1148: Phase II started

...mL oral LB1148 given 8-10 hours before undergoing elective bowel resection in about 120 patients. Leading BioSciences Inc....
BioCentury | Nov 24, 2014
Clinical News

LB1148 regulatory update

...protease inhibitor to treat multi-organ failure in septic shock and cardiogenic shock following cardiovascular surgery. Leading BioSciences Inc....
BioCentury | Feb 10, 2014
Company News

Leading BioSciences management update

Leading BioSciences Inc. , San Diego, Calif. Business: Inflammation, Diagnostic Hired: Robin Jackman as CEO and a director, formerly president and CEO of Zacharon Pharmaceuticals Inc. , which BioMarin Pharmaceutical Inc. acquired; he succeeds Interim CEO Stephen...
BioCentury | Mar 26, 2012
Clinical News

InflammaGen Shok-Pak: Phase II started

...II trial to compare InflammaGen Shok-Pak vs. standard therapy in about 200 critically-ill ICU patients. Leading BioSciences Inc....
BioCentury | Feb 13, 2012
Company News

Leading BioSciences board of directors update

Leading BioSciences Inc. , Laguna Hills, Calif. Business: Inflammation, Diagnostic Appointed: Stephen Flaim, principal at Flaim Partners Consulting, as chairman WIR Staff Diagnostic Inflammation...
BioCentury | Nov 7, 2011
Clinical News

InflammaGen Shok-Pak: Phase II start

...will begin a placebo-controlled Phase II trial to evaluate InflammaGen Shok-Pak in about 200 patients. Leading BioSciences Inc....
Items per page:
1 - 6 of 6